The Urate-Lowering Efficacy and Safety of Febuxostat in the Treatment of the Hyperuricemia of Gout: The CONFIRMS Trial

Arthritis Research and Therapy - United Kingdom
doi 10.1186/ar2978
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Febuxostat: The Evidence for Its Use in the Treatment of Hyperuricemia and Gout

Core Evidence
MedicineReviewsReferencesPharmacology
2009English

Urate Transporters: Transforming the Face of Hyperuricemia and Gout

Journal of Rheumatology
RheumatologyAllergyImmunology
2014English

The Future of Febuxostat After the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) Trial: Who CARES?

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2018English

Pleiotropic Effect of the ABCG2 Gene in Gout: Involvement in Serum Urate Levels and Progression From Hyperuricemia to Gout

Arthritis Research & Therapy
2020English

Intermittent Control of Hyperuricemia in the Treatment of Gout: 186

Pediatric Research
Child HealthPediatricsPerinatology
1985English

Adequacy of Online Patient Information Resources on Gout and Potentially Curative Urate-Lowering Treatment

Arthritis Care and Research
Rheumatology
2017English

Gout, Urate-Lowering Therapy, and Uric Acid Levels Among Adults in the United States

Arthritis Care and Research
Rheumatology
2015English

Autoinflammation in the Pathogenesis of Gout and Hyperuricemia

Clinical pharmacology and therapy
2019English

Erratum To: Comparative Effectiveness of Urate Lowering With Febuxostat Versus Allopurinol in Gout: Analyses From Large U.S. Managed Care Cohort

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy